Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Cell-based Screening Kit for Anti-human 4-1BB Antibody (Human PD-L1 Low Expression)

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

Product Specifications

Background

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

CAS Number

9007-83-4

Origin Species

Human

Target

4-1BB & PD-L1

Applications

Useful for cell-based PD-L1 binding assay Useful for PD-L1-mediated crosslinking in reporter gene assay

Format

Solid

Shipping Conditions

Dry ice

Storage Conditions

Frozen in liquid nitrogen

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

TNF alpha (J2D10), CF740 conjugate, 0.1mg/mL
BNC740994-100 1x 100 µL

TNF alpha (J2D10), CF740 conjugate, 0.1mg/mL

Sign In for Pricing
View Details
NDUFAF1 Human Gene Knockout Kit (CRISPR)
KN400029 1 Kit

NDUFAF1 Human Gene Knockout Kit (CRISPR)

Sign In for Pricing
View Details
RAPGEF3 antibody
FNab09888 100 µg

RAPGEF3 antibody

Sign In for Pricing
View Details
Recombinant DUTPase Antibody
RC-16593-01 50 μL

Recombinant DUTPase Antibody

Sign In for Pricing
View Details
Recombinant DUTPase Antibody
RC-16593-02 100 µL

Recombinant DUTPase Antibody

Sign In for Pricing
View Details
Recombinant DUTPase Antibody
RC-16593-03 1 mL

Recombinant DUTPase Antibody

Sign In for Pricing
View Details